Analyst Research

Report Title Price
Provider: S&P Capital IQ Quantitative Report
Provider: Pechala's Reports
Provider: Reuters Investment Profile
Provider: Thomson Reuters Stock Report

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

ImmunoGen Inc Announces New License Agreement

Friday, 11 Oct 2013 06:30am EDT 

ImmunoGen, Inc announced that Novartis has licensed the right to use the Company's ADC technology to develop anticancer therapeutics to an undisclosed target. This is the second license to be taken by Novartis under a 2010 agreement between the companies. 

Company Quote

0.03 +0.26%
22 Aug 2014